The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study.

BACKGROUND In recent years, some provinces have implemented income-based catastrophic drug coverage in an effort to provide universal drug coverage while limiting government liability for the escalating costs of medicines needed for an aging population. We sought to examine the effects of income-based deductibles under British Columbia's Fair PharmaCare system on older patients' use of cardiovascular medicines in 2013, 10 years after the province's policy change. METHODS Using linked administrative databases, we studied rates of hypertension and cholesterol medication used by 2 cohorts of older, married women who had different levels of public drug subsidy based solely on their spouses' ages. We compare measures of 2013 medication use by study cohorts using statistical models that controlled for age, general health status, indicators of need for specific drug classes, ethnicity, rural residence and household income. RESULTS Among members of our study cohorts, the odds of filling cardiovascular prescriptions in 2013 were influenced by patient age, general health status, drug-specific diagnoses, ethnicity, place of residence and household income. For women with household incomes less than $50 000 (42% of our study population), having preferential public drug coverage by way of spousal age was associated with a 15% increase in the adjusted odds of filling 1 or more prescription for hypertension treatment (adjusted odds ratio [OR] 1.15, 95% confidence interval [CI] 1.06 to 1.24) and a 13% increase in the adjusted odds of filling 1 or more prescription for cholesterol treatments (adjusted OR 1.13, 95% CI 1.06 to 1.21). There were no statistically significant effects on the number of days of therapy purchased per user of these cardiovascular medicines. INTERPRETATION We have found that the level of income-based deductibles under catastrophic drug benefi t plans can affect the use of cardiovascular drug treatments, even long after deductibles are put in place. These results add to the body of evidence in support of the idea that public drug coverage design can affect access to necessary medications.

[1]  S. Morgan,et al.  Whither seniors' pharmacare: lessons from (and for) Canada. , 2003, Health affairs.

[2]  S. Morgan,et al.  Income-based drug coverage in british columbia: towards an understanding of the policy. , 2006, Healthcare policy = Politiques de sante.

[3]  S. Morgan,et al.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010. , 2012, Health policy.

[4]  S. Morgan,et al.  Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked survey and administrative data , 2011, Open medicine : a peer-reviewed, independent, open-access journal.

[5]  S. Morgan,et al.  The effect of cost on adherence to prescription medications in Canada , 2012, Canadian Medical Association Journal.

[6]  S. Morgan,et al.  Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults , 2016, Age and ageing.

[7]  Mary K. Kowal,et al.  Prescription drug insurance coverage and patient health outcomes: a systematic review. , 2015, American journal of public health.

[8]  Sabrina T. Wong,et al.  Registration for public drug benefits across areas of differing ethnic composition in British Columbia, Canada , 2010, BMC health services research.

[9]  J. Tu,et al.  Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study , 2010, BMC medical research methodology.

[10]  R. Reid,et al.  Explaining Prescription Drug Use and Expenditures Using the Adjusted Clinical Groups Case-Mix System in the Population of British Columbia, Canada , 2010, Medical care.

[11]  S. Morgan,et al.  Sex Disparities in Post-Acute Myocardial Infarction Pharmacologic Treatment Initiation and Adherence: Problem for Young Women , 2015, Circulation. Cardiovascular quality and outcomes.

[12]  S. Morgan,et al.  Are Income-Based Public Drug Benefit Programs Fit for an Aging Population? , 2014 .

[13]  S. Schneeweiss,et al.  Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. , 2006, Clinical therapeutics.

[14]  S. Morgan,et al.  On the validity of area-based income measures to proxy household income , 2008, BMC health services research.

[15]  S. Soumerai,et al.  The case for a medicare drug coverage benefit: a critical review of the empirical evidence. , 2001, Annual review of public health.

[16]  S. Schneeweiss,et al.  Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. , 2007, The American journal of managed care.

[17]  J. Avorn,et al.  The impact of cost sharing on antidepressant use among older adults in British Columbia. , 2008, Psychiatric services.

[18]  S. Schneeweiss,et al.  Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment , 2007, Circulation.